Oncopeptides Logo

Oncopeptides

Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.

ONCO | ST

Overview

Corporate Details

ISIN(s):
SE0009414576 (+4 more)
LEI:
549300J9WWQ5CBYQ1M77
Country:
Sweden
Address:
Luntmakargatan 46, 111 37 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oncopeptides AB is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers, particularly hematological diseases. Founded in 2000, the company leverages its proprietary Peptide Drug Conjugate technology platforms to develop innovative treatments. Its lead product, Pepaxti® (melflufen), is a treatment for adult patients with relapsed refractory multiple myeloma (RRMM). Oncopeptides is actively commercializing Pepaxti in Europe and conducts real-world evidence studies to support the drug's effectiveness and tolerability in clinical practice. The company's mission is to address significant unmet medical needs and provide hope to cancer patients through scientific innovation.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-08 09:50
ISS
English 10.5 KB
2025-09-30 10:00
Declaration of Voting Results & Voting Rights Announcements
Antal aktier och röster i Oncopeptides
Swedish 68.1 KB
2025-09-30 10:00
Declaration of Voting Results & Voting Rights Announcements
Number of shares and votes in Oncopeptides
English 67.7 KB
2025-09-17 08:30
Share Issue/Capital Change
Oncopeptides’ rights issue oversubscribed to approximately 157 percent
English 86.0 KB
2025-09-17 08:30
Share Issue/Capital Change
Oncopeptides företrädesemission övertecknad till cirka 157 procent
Swedish 86.2 KB
2025-08-29 09:45
Major Shareholding Notification
Swedish 10.5 KB
2025-08-28 10:41
Major Shareholding Notification
Swedish 10.5 KB
2025-08-28 08:15
Share Issue/Capital Change
Oncopeptides publishes disclosure document regarding rights issue
English 91.2 KB
2025-08-28 08:15
Share Issue/Capital Change
Oncopeptides offentliggör informationsdokument avseende företrädesemission
Swedish 92.7 KB
2025-08-25 20:40
Share Issue/Capital Change
Oncopeptides enters into additional guarantee commitments, rights issue fully g…
English 83.4 KB
2025-08-25 20:40
Share Issue/Capital Change
Oncopeptides ingår ytterligare garantiåtaganden, företrädesemissionen fullt gar…
Swedish 85.1 KB
2025-08-25 10:10
Major Shareholding Notification
Swedish 10.6 KB
2025-08-21 08:00
Interim Report
Swedish 580.9 KB
2025-08-21 08:00
Interim Report
English 597.7 KB
2025-08-21 07:59
Share Issue/Capital Change
Oncopeptides carries out rights issue of approximately SEK 150 million and prov…
English 110.4 KB

Automate Your Workflow. Get a real-time feed of all Oncopeptides filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Oncopeptides via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-04-15 David Augustsson Other Buy 1,250 6,350.00 SEK
2024-04-15 David Augustsson Other Buy 1,250 6,312.50 SEK
2024-04-15 David Augustsson Other Buy 438 2,225.04 SEK
2024-04-15 David Augustsson Other Buy 60 303.60 SEK
2024-04-15 David Augustsson Other Buy 2 10.02 SEK
2023-09-08 David Augustsson Other Buy 2,296 17,706.75 SEK
2023-08-10 David Augustsson Other Buy 1,704 14,995.20 SEK
2023-05-04 Nicolaas Bakker Other Buy 5,000 42,380.00 SEK
2022-10-10 Nicolaas Bakker Other Buy 15,000 164,400.00 SEK
2022-08-30 Per Wold-Olsen Other Buy 2,050 55,350.00 SEK

Peer Companies

Company Country Ticker View
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden IBT
Intercure Ltd. Logo
Develops and distributes pharmaceutical-grade medical cannabis for patients and pharmacies globally.
Israel INCR
Intervacc AB Logo
Develops recombinant protein vaccines and diagnostics for animal health, like Strangvac® for horses.
Sweden IVACC
iNtRON Biotechnology, Inc. Logo
Develops phage therapeutics and molecular diagnostics to combat infectious diseases.
South Korea 048530
Inventage Lab Inc. Logo
Develops drug delivery systems using microfluidics for chronic diseases and gene therapies.
South Korea 389470
Ipsen Logo
Developing innovative medicines for Oncology, Rare Diseases, and Neuroscience.
France IPN
IRLAB Therapeutics Logo
Developing novel drugs for Parkinson's disease and other neurodegenerative CNS disorders.
Sweden IRLAB
ISU Abxis Co., Ltd. Logo
Developing antibody-based immunotherapies for oncology and rare diseases.
South Korea 086890
IVF HARTMANN Holding AG Logo
Produces and distributes medical supplies, wound care, and hygiene items for global healthcare.
Switzerland VBSN
Japan Tissue Engineering Co., Ltd. Logo
Pioneers regenerative medicine with tissue products, CDMO services, and research models.
Japan 7774

Talk to a Data Expert

Have a question? We'll get back to you promptly.